Skip to site menu Skip to page content
Curia Global
Go back
Download Product

Thank you.

Please check your email to download the Product.

Aseptic Processing

For many therapies, achieving sterility at the active ingredient stage is a demanding and highly specialised undertaking that requires rigorous control at every step. Curia offers dedicated sterile API manufacturing capabilities, applying advanced aseptic techniques to produce high-quality drug substances for parenteral and other sterile applications, from clinical development through commercial supply.

With more than two decades of experience in aseptic API production, Curia operates specialised suites engineered to minimise the risk of microbial, particulate, and endotoxin contamination. The company’s facilities feature isolator-based, fully closed systems, supported by advanced automation, controlled environments, and modern sterilisation technologies aligned with the latest EU GMP Annex 1 standards. This infrastructure enables the safe handling of complex molecules, including potent compounds and steroids, while ensuring consistent product quality and regulatory compliance.

Backed by continued investment in equipment, process understanding, and data integrity controls, Curia helps clients navigate the complexities of sterile drug substance production, delivering the precision, reliability, and quality assurance essential for advancing sterile APIs to market.

Related Content